Enlarged Prostate (BPH)NCT07632742
Moses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial
A study testing Magneto 150 holmium laser and Moses 2.0 holmium laser in people with Enlarged Prostate (BPH) and Benign Prostatic Hyperplasia, run by Northwestern University at 1 site in United States.
Trial summary
The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively. Read more about this study
- Who is it for?
- Ages 18 to 100 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Enlarged Prostate (BPH), Benign Prostatic Hyperplasia
- What is being tested?
- Magneto 150 holmium laser and Moses 2.0 holmium laser
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 180 participants
- Where
- 1 siteUnited States
- Study dates
- 29 May 2026to Jun 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms
- Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)
Who cannot join
- Patients who lack decisional capacity
- Patients unable to read/speak English
- Patients who are on a blood thinner (anticoagulation medication)
- Patients who do not have internet access to complete postoperative surveys
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Northwestern University
Chicago, Illinois, 60611
Alyssa McDonald, MPH, 312-695-8146, alyssa.mcdonald@northwestern.edu
About this study
Official title: MOSES 2.0 vs Quanta Magneto 150 Holmium Laser for Holmium Laser Enucleation of the prostate-a Randomized Controlled Trial
The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.
Read the detailed description
The Magneto 150 is a high-powered 150W holmium laser that offers similar pulse-modulation benefits of MOSES 2.0, which facilitates effective dissection and enucleation of the tissue plane while also offering a new first-of-its kind proprietary Magneto setting which allows for very low peak power of 500W and longer pulse duration which allows for better hemostasis.
- Being tested
- Magneto 150 holmium laser, Moses 2.0 holmium laser
- Keywords
- HoLEP, Holmium laser
- Medical subject headings
- Prostatic Hyperplasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magneto 150 holmium laserDevice
The HoLEP procedure will be performed using the Quanta Magneto 150 holmium laser
Moses 2.0 holmium laserDevice
The HoLEP procedure will be performed using the Moses 2.0 holmium laser
| Study group | Role | What they receive |
|---|---|---|
| Moses 2.0 | Active comparator | HoLEP procedure performed using the Moses 2.0 holmium laser Receives: Device: Moses 2.0 holmium laser |
| Magneto 150 | Experimental | HoLEP procedure performed using Magneto 150 holmium laser Receives: Device: Magneto 150 holmium laser |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean hemostasis time
Overall intraoperative hemostasis time
Measured: During surgery
Secondary outcomes (3)
Mean (average) enucleation time
Time taken to surgically remove excess prostate tissue while leaving the shell of the prostate intact and within the body.
Measured: During surgery
Total operative time
Time taken from official procedure start to completion (not accounting for the time that the patient is wheeled in, prepped and out of the operating room).
Measured: During surgery
Hemostasis efficiency
minutes/gram (prostate tissue removed)
Measured: During surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jun 2026
- Study start29 May 2026
- Primary completionJun 2027 (estimated)
- Study completionJun 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Enlarged Prostate (BPH)Studies of the same condition, open and under way.
- More trials run by Northwestern UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 180 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Collaborators
- Cook Group Incorporated
- Responsible party
- Principal investigator, Amy Krambeck, Northwestern University
- Investigators
- Perry Xu, MD, Principal investigator, Northwestern University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07632742
- Sponsor's protocol ID
- STU00225001
- Status last verified
- Apr 2026
- First submitted
- 2 Jun 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- MOSES 2.0 vs Quanta Magneto 150 Holmium Laser for Holmium Laser Enucleation of the prostate-a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07632742
- Acronym / sponsor ID
- STU00225001
- Keywords
- HoLEP, Holmium laser
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 180 participants (estimated)
- Lead sponsor
- Northwestern UniversityUniversity, hospital or other
- Collaborators
- Cook Group Incorporated
- Study start
- 29 May 2026 (actual)
- Primary completion
- Jun 2027 (estimated)
- Study completion
- Jun 2028 (estimated)
- First posted
- 8 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.
Detailed description
The Magneto 150 is a high-powered 150W holmium laser that offers similar pulse-modulation benefits of MOSES 2.0, which facilitates effective dissection and enucleation of the tissue plane while also offering a new first-of-its kind proprietary Magneto setting which allows for very low peak power of 500W and longer pulse duration which allows for better hemostasis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Moses 2.0 | Active comparator | Device: Moses 2.0 holmium laserHoLEP procedure performed using the Moses 2.0 holmium laser |
| Magneto 150 | Experimental | Device: Magneto 150 holmium laserHoLEP procedure performed using Magneto 150 holmium laser |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Undergoing HoLEP for the treatment of bothersome lower urinary tract symptoms
- Internet access and a device to complete postoperative questionnaires (smartphone, tablet, laptop or desktop computer)
Key exclusion criteria (4 listed)
- Patients who lack decisional capacity
- Patients unable to read/speak English
- Patients who are on a blood thinner (anticoagulation medication)
- Patients who do not have internet access to complete postoperative surveys
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magneto 150 holmium laserThe HoLEP procedure will be performed using the Quanta Magneto 150 holmium laser | Device | Magneto 150 |
| Moses 2.0 holmium laserThe HoLEP procedure will be performed using the Moses 2.0 holmium laser | Device | Moses 2.0 |
Primary outcome
Mean hemostasis time
Time frame: During surgery
Overall intraoperative hemostasis time
3 secondary outcomes
Mean (average) enucleation time
Time frame: During surgery
Total operative time
Time frame: During surgery
Hemostasis efficiency
Time frame: During surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Enlarged Prostate (BPH)
Enrolling by invitation
Emsella for Reducing tSUI After HOLEP
Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms
Not yet recruitingPhase 4
Prospective Post Market Clinical Trial for the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH.
Benign Prostatic Hyperplasia (BPH), Obstructive Lower Urinary Tract Symptoms (LUTS)
Recruiting
Ejaculatory-Sparing HoLEP vs Standard HoLEP
Enlarged Prostate (BPH), Enlarged Prostate With Lower Urinary Tract Symptoms
Active, not recruiting
Long Term Safety and Efficacy of Butterfly Medical Prostatic Retraction Device in Benign Prostatic Hyperplasia (BPH) Patients Who Completed 12 Months of Follow-Up Post Implantation (Continuation Study for Study BM-011-IL)
BPH, BOO - Bladder Outflow Obstruction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Perry Xu, MD principal investigator
Northwestern University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Magneto 150 holmium laser and Moses 2.0 holmium laser in people with Enlarged Prostate (BPH) and Benign Prostatic Hyperplasia, run by Northwestern University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Alyssa McDonald, MPH (312-695-8146, alyssa.mcdonald@northwestern.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean hemostasis time (time frame: During surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026; AzTrials last refreshed its copy on 29 Oct 2026.